Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
The Clinical Value of Two Combination Regimens in the Management of Patients Suffering From Covid-19 Pneumonia: A Single Centered, Retrospective, Observational Study Publisher Pubmed



Vahedi E1 ; Ghanei M1 ; Ghazvini A1 ; Azadi H1 ; Izadi M2 ; Panahi Y3 ; Fathi S4 ; Salesi M1 ; Saadat SH5 ; Ghazale AH6 ; Rezapour M6 ; Mozafari A7 ; Zand N8 ; Parsaei MR6 Show All Authors
Authors
  1. Vahedi E1
  2. Ghanei M1
  3. Ghazvini A1
  4. Azadi H1
  5. Izadi M2
  6. Panahi Y3
  7. Fathi S4
  8. Salesi M1
  9. Saadat SH5
  10. Ghazale AH6
  11. Rezapour M6
  12. Mozafari A7
  13. Zand N8
  14. Parsaei MR6
  15. Ranjkesh MH6
  16. Jafari R9
  17. Movaseghi F7
  18. Darabi E10

Source: DARU# Journal of Pharmaceutical Sciences Published:2020


Abstract

Background: There is no identified pharmacological therapy for COVID-19 patients, where potential therapeutic strategies are underway to determine effective therapy under such unprecedented pandemic. Therefore, combination therapies may have the potential of alleviating the patient’s outcome. This study aimed at comparing the efficacy of two different combination regimens in improving outcomes of patients infected by novel coronavirus (COVID-19). Methods: This is a single centered, retrospective, observational study of 60 laboratory-confirmed COVID-19 positive inpatients (≥18 years old) at two wards of the Baqiyatallah Hospital, Tehran, Iran. Patient’s data including clinical and laboratory parameters were recorded. According to the drug regimen, the patients were divided into two groups; group I who received regimen I consisting azithromycin, prednisolone, naproxen, and lopinavir/ritonavir and group II who received regimen II including meropenem, levofloxacin, vancomycin, hydroxychloroquine, and oseltamivir. Results: The oxygen saturation (SpO2) and temperature were positively changed in patients receiving regimen I compared to regimen II (P = 0.013 and P = 0.012, respectively). The serum level of C-reactive protein (CRP) changed positively in group I (P < 0.001). Although there was a significant difference in platelets between both groups (75.44 vs 51.62, P < 0.001), their change did not clinically differ between two groups. The findings indicated a significant difference of the average length of stay in hospitals (ALOS) between two groups, where the patients under regimen I showed a shorter ALOS (6.97 vs 9.93, P = 0.001). Conclusion: This study revealed the beneficial effect of the short-term use of low-dose prednisolone in combination with azithromycin, naproxen and lopinavir/ritonavir (regimen I), in decreasing ALOS compared to regimen II. Since there is still lack of evidence for safety of this regimen, further investigation in our ongoing follow-up to deal with COVID-19 pneumonia is underway. [Figure not available: see fulltext.] © 2020, Springer Nature Switzerland AG.
Other Related Docs
8. Ten Challenging Questions About Sars-Cov-2 and Covid-19, Expert Review of Respiratory Medicine (2020)
10. Cancer Care Management During the Covid-19 Pandemic, Risk Management and Healthcare Policy (2020)
17. Analyzing Trends in Demographic, Laboratory, Imaging, and Clinical Outcomes of Icu-Hospitalized Covid-19 Patients, Canadian Journal of Infectious Diseases and Medical Microbiology (2023)